^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Pediatric Acute Lymphoblastic Leukemia: Regimen components…Consolidation…For CRLF2+ or CRLF2- with JAK2 fusions, EPOR rearrangement, SH2B3 alterations, IL7R insertions/deletions: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + ruxolitinib; IT therapy: methotrexate